| 1 |
Liu Y, Liu HL, Geng GY, et al. Effects of coronary arterial injection of tirofiban on diabetes mellitus complicated with acute myocardial infarction in the elderly[J]. Acta Cardiol Sin, 2013, 29 (6): 550-556.
|
| 2 |
周发展，武君，张春玲，等. 替罗非班应用于急诊经皮冠状动脉介入治疗对急性心肌梗死患者心肌灌注和内皮功能的影响[J/CD]. 中华危重症医学杂志（电子版），2016，9(1):3-8.
|
| 3 |
Ostrowska M, Adamski P, Koziński M, et al. Off-target effects of glycoprotein Ⅱb/Ⅲa receptor inhibitors[J]. Cardiol J, 2014, 21 (5): 458-464.
|
| 4 |
Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37 (3): 267-315.
|
| 5 |
Giordano A, Musumeci G, D'Angelillo A, et al. Effects of glycoprotein Ⅱ b/Ⅲ a antagonists: anti platelet aggregation and beyond[J]. Curr Drug Metab, 2016, 17 (2): 194-203.
|
| 6 |
Zhou SS, Tian F, Chen YD, et al. Combination therapy reduces the incidence of no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevationacute myocardial infarction[J]. JGeriatr Cardiol, 2015, 12 (2): 135-142.
|
| 7 |
Valgimigli M, Campo G, Malagutti P, et al. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials[J]. JACC Cardiovasc Interv, 2011, 4 (1): 51-62.
|
| 8 |
赵雯洁，王琛，孙波，等. 硫化氢后处理对2型糖尿病大鼠心肌缺血再灌注损伤的保护作用及其与自噬潮的相关性研究[J/CD]. 中华危重症医学杂志（电子版），2016，9(2):81-86.
|
| 9 |
Sun Z, Zeng J, Huang H. Intracoronary injection of tirofiban prevents microcirculation dysfunction during delayed percutaneous coronary intervention in patients with acute myocardial infarction[J]. Int J Cardiol, 2016 (208): 137-140.
|
| 10 |
Timmer JR, ten Berg J, Heestermans AA, et al. Prehospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of theOn-Time 2 trial[J]. EuroIntervention, 2010, 6 (3): 336-342.
|
| 11 |
Yan HB, Li SY, Song L, et al. Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction[J]. Chin Med J (Engl), 2010, 123 (7): 877-883.
|
| 12 |
Gao L, Cao Z, Zhang H. Efficacy and safety of thrombectomy combined with intracoronary administration of tirofiban in ST-segment elevation myocardial infarction (STEMI)[J]. Med Sci Monit, 2016 (22): 2699-2705.
|
| 13 |
Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials[J]. Eur Heart J, 2010, 31 (1): 35-49.
|
| 14 |
Friedland S, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein Ⅱ b/Ⅲ a inhibitors during percutaneous coronary intervention for acute coronary syndrome[J]. Am J Cardiol, 2011, 108 (9): 1244-1251.
|